BeiGene Medical Europe
 acceso
 
  • Congreso virtual
  • Contacto
  • memoinOncology
  • beigenemedical.info

memo inOncology – Congress Report ESMO 2019

 Volver  Ver
memo inOncology – Congress Report ESMO 2019
 PDF   24   10/2020
 Ver

A global digest on approaches in advanced solid tumors

Rating

Rate this publication

Publicaciones relacionadas

BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer
BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer
Safety and efficacy of long-term exposure (LTE) to tislelizumab in chinese patients with advanced solid tumors
Safety and efficacy of long-term exposure (LTE) to tislelizumab in chinese patients with advanced solid tumors
Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer
Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer
 Volver

Esta función sólo está disponible para usuarios registrados.

BeiGene Medical EU
Bienvenido al sitio web de información médica de BeiGene EU
EuropeWorldItalySpain
No soy un profesional de la salud
Ahora está saliendo del sitio web de BeiGene EU.
You are now leaving the italian website of BeiGene EU.
BeiGene Medical EU
Please check your webbrowser
BeiGene Medical Europe
beigenemedical.eu
  • Congreso virtual
Este sitio web contiene información sobre productos de investigación que aún no han sido aprobados por la Agencia Europea del Medicamento para el tratamiento de ninguna enfermedad. Para más información, contacte con medicalinformationEU@beigene.com.
© 2022 BeiGene. All Rights Reserved.
Política de privacidad | Condiciones | Publicado por |